Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN beta

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360950" target="_blank" >RIV/00216208:11110/17:10360950 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/17:10360950 RIV/00064203:_____/17:10360950 RIV/00023884:_____/12:00007375 RIV/00064165:_____/17:10360950

Výsledek na webu

<a href="http://dx.doi.org/10.1371/journal.pone.0169957" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0169957</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0169957" target="_blank" >10.1371/journal.pone.0169957</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN beta

Popis výsledku v původním jazyce

Introduction Interferon-beta (IFNss) is the first-line treatment for relapsing-remitting multiple sclerosis. Myxovirus resistance protein A (MxA) is a marker of IFNss bioactivity, which may be reduced by neutralizing antibodies (NAbs) against IFNss. The aim of the study was to analyze the kinetics of MxA mRNA expression during long-term IFNss treatment and assess its predictive value. Methods A prospective, observational, open-label, non-randomized study was designed in multiple sclerosis patients starting IFNss treatment. MxA mRNA was assessed prior to initiation of IFNss therapy and every three months subsequently. NAbs were assessed every six months. Assessment of relapses was scheduled every three months during 24 months of follow up. The disease activity was correlated to the pretreatment baseline MxA mRNA value. In NAb negative patients, clinical status was correlated to MxA mRNA values. Results 119 patients were consecutively enrolled and 107 were included in the final analysis. There was no correlation of MxA mRNA expression levels between baseline and month three. Using survival analysis, none of the selected baseline MxA mRNA cut off points allowed prediction of time to first relapse on the treatment. In NAb negative patients, mean MxA mRNA levels did not significantly differ in patients irrespective of relapse status. Conclusion Baseline MxA mRNA does not predict the response to IFNss treatment or the clinical status of the disease and the level of MxA mRNA does not correlate with disease activity in NAb negative patients.

Název v anglickém jazyce

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN beta

Popis výsledku anglicky

Introduction Interferon-beta (IFNss) is the first-line treatment for relapsing-remitting multiple sclerosis. Myxovirus resistance protein A (MxA) is a marker of IFNss bioactivity, which may be reduced by neutralizing antibodies (NAbs) against IFNss. The aim of the study was to analyze the kinetics of MxA mRNA expression during long-term IFNss treatment and assess its predictive value. Methods A prospective, observational, open-label, non-randomized study was designed in multiple sclerosis patients starting IFNss treatment. MxA mRNA was assessed prior to initiation of IFNss therapy and every three months subsequently. NAbs were assessed every six months. Assessment of relapses was scheduled every three months during 24 months of follow up. The disease activity was correlated to the pretreatment baseline MxA mRNA value. In NAb negative patients, clinical status was correlated to MxA mRNA values. Results 119 patients were consecutively enrolled and 107 were included in the final analysis. There was no correlation of MxA mRNA expression levels between baseline and month three. Using survival analysis, none of the selected baseline MxA mRNA cut off points allowed prediction of time to first relapse on the treatment. In NAb negative patients, mean MxA mRNA levels did not significantly differ in patients irrespective of relapse status. Conclusion Baseline MxA mRNA does not predict the response to IFNss treatment or the clinical status of the disease and the level of MxA mRNA does not correlate with disease activity in NAb negative patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NT12385" target="_blank" >NT12385: Sledování exprese mRNA MxA jako markeru biologické účinnosti interferonů ß u pacientů s roztroušenou sklerózou</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS One

ISSN

1932-6203

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000391949500108

EID výsledku v databázi Scopus

2-s2.0-85009384626